Navigation Links
SPI Pharma Gains Ground in Roquette Patent Dispute
Date:6/17/2010

WILMINGTON, Del., June 17 /PRNewswire/ -- On Friday June 11th, Chief Judge Gregory Sleet of the United States District Court for the District of Delaware issued an important pre-trial ruling in the long-running patent dispute between SPI Pharma and Roquette Freres.  

The court's ruling narrowly defined several key phrases contained in Roquette's patent claims, thereby dealing a significant blow to Roquette's allegations of patent infringement. Chief Judge Sleet issued his ruling after hearing extensive oral arguments in open court on May 11th. The case is scheduled to go to trial beginning October 4th.  

SPI Pharma's President, Rana Kayal, was very pleased with the decision: "This ruling by the court strongly supports our long-held position that SPI Pharma's Mannogem EZ and Pharmaburst® products do not infringe on Roquette's patent. SPI Pharma will continue to defend itself against Roquette's baseless allegations of patent infringement, and we look forward to presenting our case to the jury at the trial to be held in October."    

SPI Pharma is a global leader with sales in over 55 countries in the manufacture and marketing of antacid actives, excipients, drug delivery systems for tablets, soft gel capsules, fast-dissolve technologies, chewables, lozenges, and a variety of other patient-friendly dosage forms. SPI also specializes in drug development services. For more information, visit

SOURCE SPI Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... Stimulating nerves in your ear could improve the health ... at the University of Leeds used a standard TENS ... apply electrical pulses to the tragus, the small raised ... front of the ear canal. , The stimulation changed ... by reducing the nervous signals that can drive failing ...
(Date:8/20/2014)... Sofia, Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the ... rates and connectors for Lucene, SOLR and Elasticsearch. ... change for this high performance triplestore – GraphDB™ ... organizations interested in deploying the only mature enterprise ...
(Date:8/19/2014)... August 19, 2014 Shimadzu Scientific ... systems, Prominence-i and Nexera-i, adding to the company’s ... excellent functionality, an intuitive operating environment, and full ... more efficient workflow for conventional to ultra-high-speed analysis. ... intuitive and intelligent design so users can begin ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... ever involving patients with cutaneous T-cell lymphoma on schedule ... RADNOR, Pa., June 29 Yaupon Therapeutics, a privately ... enrollment for a pivotal Phase 2 clinical trial for ... (CTCL - stages 1-2a). The study, which is ...
... DOR BioPharma, Inc. ... late-stage biopharmaceutical company, announced today that investigators at the ... paper this morning in Bone Marrow Transplantation ... (oral beclomethasone dipropionate or BDP) decreases non-infectious inflammation of ...
... 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... product development company that identifies and advances a ... stages of development, today reported that YM,s subsidiary, ... the issues between the companies in a cooperative ...
Cached Biology Technology:Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 3DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 4DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 5DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 6YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 2YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 3YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 4
(Date:8/21/2014)... implications for life in other extreme environments, both on ... Associate Professor of Biological Sciences Brent Christner and fellow ... this week published a paper confirming that the waters ... (2600 feet) beneath the surface of the West Antarctic ... than 400 subglacial lakes and numerous rivers and streams ...
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
Breaking Biology News(10 mins):800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4American Society of Human Genetics 2014 Annual Meeting 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... Hopkins have discovered that a tiny piece of genetic code ... and it gets there under its own internal code. , ... that directs its movement, will be published Jan. 5 in ... development, latch on to and gum up larger strands of ...
... risk factor for Alzheimer's disease puts out the welcome mat for ... more active in the brain compared to other forms of the ... Aging, add some scientific heft to the idea, long suspected by ... Alzheimer's disease. , The work links a form of the ApoE ...
... percent of men treated with a combination of radiation ... cancer are cured of their disease 15 years following ... the International Journal of Radiation Oncology*Biology*Physics, the official journal ... physicians at the Seattle Prostate Institute. Doctors wanted to ...
Cached Biology News:Renegade RNA -- Clues to cancer and normal growth 2Cold sore virus might play role in Alzheimer's disease 2Cold sore virus might play role in Alzheimer's disease 3Cold sore virus might play role in Alzheimer's disease 4
... The Nick Translation System is ideal ... DNA. The Nick Translation System: Provides ... labeled nucleotide incorporation Yields >10 8 ... Includes control DNA to monitor the performance ...
... portable, easy-to-use and makes identifying your samples more ... to use Labels withstand extreme lab ... Time/Date stamp Laboratory symbols ... Serialization feature makes you more efficient ...
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
Biology Products: